Dissecting TMEM63A mediated calcium signaling and lipid scramblase activity in myelination

Active Grant Awarded

Award ID
FNS153682UJKN51
Recipient
Awarding agency
Obligated
$50,114

Award facts

Assistance listing
93.NS5 Neurosciences and Neurological Disorders – Training, Individual (TR)
Completion date 1% complete
Place of performance
Portland, OR 97239, USA

Award details come from USAspending.gov.

Description

Abstract
In the central nervous system (CNS), oligodendrocytes (OLS) produce myelin, the lipid-rich coating on axons that increases the speed of action potential conduction and supports neuronal health. OLS differentiate from OL precursor cells, integrating soluble factors, permissive and repulsive membrane-bound axonal cues, and mechanical input to guide myelination. Heterozygous mutations in TMEM63A, a mechanically activated ION channel, lead to hypomyelinating leukodystrophy (HLD19), a rare neurological disorder characterized by impaired myelin formation during development accompanied by motor and cognitive deficits. TMEM63A has historically been classified as a mechanosensitive CA2+‑permeable ION channel; however, recent structural and functional studies raise the possibility that TMEM63A also functions as a lipid scramblase. How these two proposed functions contribute to normal myelination and to disease pathogenesis remains unknown. This project will test the hypothesis that TMEM63A‑associated leukodystrophy is not explained solely by loss of CA2+ signaling, but that certain human disease mutations cause a toxic gain‑of‑function (GOF) in lipid scramblase activity that disrupts OL development and myelin formation. I will use a combination of in vitro biophysical assays and in vivo functional analyses in zebrafish to dissect how TMEM63A regulates myelination and how disease‑associated mutations impact its ION VS. Lipid channel function. Preliminary data shows that expression of a lipid scramblase GOF mutant is detrimental to OL development in vivo and that the human disease mutant G553V has GOF scramblase activity. Aim 1 will determine whether human HLD19 mutations alter TMEM63A lipid scramblase activity and assess the developmental consequences of altered lipid scrambling in OLS. Human disease variants will be tested for their ability to scramble membrane lipids in heterologous systems using an annexin V binding assay. These experiments will distinguish loss‑of‑function mutations from lipid scramblase GOF variants. Aim 2 will investigate whether HLD19 mutations disrupt TMEM63A‑mediated CA2+ signaling and how changes in TMEM63A‑dependent CA2+ dynamics influence OL development. By visualizing TMEM63A- specific CA2+ activity using a tethered CA2+ indicator approach and live imaging in zebrafish, this aim will define how disease mutations alter CA2+ permeability, subcellular localization of CA2+ signals, and downstream developmental outcomes. This work will provide the first in vivo dissection of TMEM63A's ION channel and lipid scramblase functions in myelination. By establishing how distinct molecular activities of TMEM63A contribute to normal development and disease, this project will clarify the mechanisms underlying TMEM63A‑associated leukodystrophy and identify the most relevant targets for therapeutic intervention. More broadly, these studies will advance fundamental understanding of how CA2+ signaling and membrane lipid regulation converge to control myelin formation in the developing CNS.

Quick answers

Who received award FNS153682UJKN51?

FNS153682UJKN51 was awarded to Oregon Health & Science University by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on November 16, 2026.

How much is award FNS153682UJKN51 worth?

$50,114 has been obligated on FNS153682UJKN51.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award